Theralase Technologies Inc. (TLTFF)

Compare

0.1300

-0.0005

(-0.38%)

At close: April 4 at 4:00:00 PM EDT

Ruvidar Effective in the Treatment of Herpes

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, inten

Newsfile 13 days ago

TLTFF
-0.38%
Theralase Technologies Full Year 2024 Earnings: Beats Expectations

Theralase Technologies ( CVE:TLT ) Full Year 2024 Results Key Financial Results Revenue: CA$1.03m (down 3.4% from FY...

Simply Wall St. 21 days ago

TLTFF
-0.38%
Theralase(R) Releases 2024 Annual Financial Statements

Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period

Newsfile 25 days ago

TLTFF
-0.38%
Theralase(R) Closes Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering

Newsfile 26 days ago

TLTFF
-0.38%
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients

Parkinson's Patients Have Improved Motor and Non-Motor Function After Treatment with Theralase(R) Cool Laser Therapy Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, b

Newsfile 27 days ago

TLTFF
-0.38%
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma

Rutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively destroy Non-Hodgkin's Lymphoma in an animal model. Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective d

Newsfile last month

TLTFF
-0.38%
Theralase(R) Demonstrates Effective Treatment of Herpes

Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, ...

ACCESS Newswire last month

TLTFF
-0.38%
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses

Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, ...

ACCESS Newswire last month

TLTFF
-0.38%
February 2025 TSX Penny Stocks To Watch

The Canadian market is currently navigating a period of economic uncertainty, with the Bank of Canada cutting rates due to potential U.S. tariffs and a recent contraction in GDP. Despite these challenges, the concept of penny stocks—often representing smaller or newer companies—remains relevant for investors seeking opportunities at lower price points. By focusing on those with strong financial fundamentals, penny stocks can offer hidden potential without many of the associated risks, making...

Simply Wall St. last month

MFGCF

CCARF

TLTFF
-0.38%
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, ...

ACCESS Newswire 2 months ago

TLTFF
-0.38%
TSX Penny Stocks To Watch: 3 Picks Under CA$200M Market Cap

As the Canadian market reflects on a strong 2024, marked by an 18% gain in the TSX and robust performances across sectors, investors are now navigating a landscape of mixed economic signals and policy uncertainties. Amidst this backdrop, smaller companies often referred to as penny stocks continue to attract attention for their potential value and growth opportunities. While the term "penny stocks" may seem outdated, these investments can offer surprising stability when backed by solid...

Simply Wall St. 2 months ago

GENGF

TLTFF
-0.38%
DCMDF
Theralase(R) Launches Three New Clinical Study Sites in USA

Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, ...

ACCESS Newswire 3 months ago

TLTFF
-0.38%
December 2024 TSX Penny Stocks: Opportunities To Consider

The Canadian market has shown resilience, supported by easing monetary policies and strong performances in sectors like financials and materials. For investors looking at smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer intriguing opportunities. By focusing on those with robust financials and growth potential, these stocks may present a unique blend of value and stability in today's economic landscape.

Simply Wall St. 3 months ago

TLTFF
-0.38%
PSHIF

GENGF
Theralase(R) Launches New Clinical Study Site in Canada

St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / ACCESSWIRE / December 5, 2024 / Theralase® Technologies Inc. ...

ACCESS Newswire 3 months ago

TLTFF
-0.38%
Theralase Technologies Third Quarter 2024 Earnings: CA$0.004 loss per share (vs CA$0.005 loss in 3Q 2023)

Theralase Technologies ( CVE:TLT ) Third Quarter 2024 Results Key Financial Results Revenue: CA$346.6k (up 24% from 3Q...

Simply Wall St. 4 months ago

TLTFF
-0.38%
Theralase(R) Release’s 3Q2024 Financial Statements

Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, ...

ACCESS Newswire 4 months ago

TLTFF
-0.38%
Theralase(R) Extends Warrants

TORONTO, ON / ACCESSWIRE / November 12, 2024 / Theralase® Technologies Inc. ("Theralase ®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or ...

ACCESS Newswire 4 months ago

TLTFF
-0.38%
When Will Theralase Technologies Inc. (CVE:TLT) Become Profitable?

With the business potentially at an important milestone, we thought we'd take a closer look at Theralase Technologies...

Simply Wall St. 4 months ago

TLTFF
-0.38%
Theralase(R) Provides Update on Bladder Cancer Clinical Study

TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or ...

ACCESS Newswire 5 months ago

TLTFF
-0.38%
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options

TORONTO, ON / ACCESSWIRE / September 24, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or ...

ACCESS Newswire 6 months ago

TLTFF
-0.38%

Performance Overview

Return	TLTFF	S&P/TSX Composite index (^GSPTSE)
YTD	-27.78%	-5.80%
1-Year	+8.33%	+5.18%
3-Year	-64.86%	+5.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Theralase Technologies Inc. (TLTFF)

Ruvidar Effective in the Treatment of Herpes

Theralase Technologies Full Year 2024 Earnings: Beats Expectations

Theralase(R) Releases 2024 Annual Financial Statements

Theralase(R) Closes Non-Brokered Private Placement

Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients

Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma

Theralase(R) Demonstrates Effective Treatment of Herpes

Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses

February 2025 TSX Penny Stocks To Watch

Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

TSX Penny Stocks To Watch: 3 Picks Under CA$200M Market Cap

Theralase(R) Launches Three New Clinical Study Sites in USA

December 2024 TSX Penny Stocks: Opportunities To Consider

Theralase(R) Launches New Clinical Study Site in Canada

Theralase Technologies Third Quarter 2024 Earnings: CA$0.004 loss per share (vs CA$0.005 loss in 3Q 2023)

Theralase(R) Release’s 3Q2024 Financial Statements

Theralase(R) Extends Warrants

When Will Theralase Technologies Inc. (CVE:TLT) Become Profitable?

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options

Performance Overview